

ICMJE Form for Disclosure of Potential Conflicts of Interest

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

patent



Identifying Information

Section 1.

ICMJE Form for Disclosure of Potential Conflicts of Interest

1. Given Name (First Name) Vivian	2. Surnan Bykerk	ne (Last Nar	ne)		3. Date 06-February-2020	
4. Are you the corresponding author?	✓ Yes	No				
5. Manuscript Title A Reminder to Systematically Monitor f	or Adverse	Events in	Users of Low Dos	e Methot	rexate Therapy	
6. Manuscript Identifying Number (if you kr M20-0435	now it)					
Section 2. The Work Under Co	onsiderat	tion for P	ublication			
Did you or your institution at any time rece any aspect of the submitted work (including statistical analysis, etc.)?						:c.) for
Are there any relevant conflicts of interest	est?	∕es ✓	No			
Section 3. Relevant financial	activities	outside t	the submitted	work.		
Place a check in the appropriate boxes of compensation) with entities as descr clicking the "Add +" box. You should re	ibed in the	instruction	ns. Use one line fo	or each er	ntity; add as many lines as you need	d by
Are there any relevant conflicts of interest			No			
If yes, please fill out the appropriate info	ormation b	elow.				
Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments	
Amgen		√			Consulting	
BMS		✓			Consulting	
Gilead					Consulting	
Pfizer		✓			Consulting	
Genzyme Corporation		✓			Consulting	
Novartis			✓		Education Discussion	
Regeneron Pharmaceuticals		✓			Consulting	



ICMJE Form for Disclosure of Potential Conflicts of Interest

NH (NIAID/NIAMS) 1UH2AR067691-01 Ganation Given to the Institution Given to the Institution Ganation Given to the Institution Given to Institution Given to Institution Given to Institution Given to the Institution Given to Institutio	Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments				
Canadian Institute for Health Research (CIHR) Grant given to Institution - no personal fees KAI for NIAMS United Chemicals of Belgium Family Member an Employee Section 4. Intellectual Property Patents & Copyrights Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes No Section 5. Relationships not covered above Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work? Yes, the following relationships/conditions/circumstances are present (explain below): No other relationships/conditions/circumstances that present a potential conflict of interest Dr Bykerk has participated in research on developing a means for systematic capture of safety data as a member of the	,	✓				Given to the Institution				
DSMB Double DSMB District Dsmb D	Cedar Hill Foundation	✓				Given to the Institution				
United Chemicals of Belgium	Canadian Institute for Health Research (CIHR)			✓						
Brainstorm Therapeutics Family Member an Employee	KAI for NIAMs		\checkmark			DSMB				
Section 4. Intellectual Property Patents & Copyrights Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes No Section 5. Relationships not covered above Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work? Yes, the following relationships/conditions/circumstances are present (explain below): No other relationships/conditions/circumstances that present a potential conflict of interest Dr Bykerk has participated in research on developing a means for systematic capture of safety data as a member of the	United Chemicals of Belgium		\checkmark			Consulting				
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes No Section 5. Relationships not covered above Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work? Yes, the following relationships/conditions/circumstances are present (explain below): No other relationships/conditions/circumstances that present a potential conflict of interest Dr Bykerk has participated in research on developing a means for systematic capture of safety data as a member of the	Brainstorm Therapeutics				√	Family Member an Employee				
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work? Yes, the following relationships/conditions/circumstances are present (explain below): No other relationships/conditions/circumstances that present a potential conflict of interest Dr Bykerk has participated in research on developing a means for systematic capture of safety data as a member of the	Section 5. Polotionaling not covered above									

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.



ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 6.

Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Bykerk reports personal fees from Amgen, BMS, Gilead, Pfizer, Genzyme Corporation, Regeneron Pharmaceuticals, and United Chemicals of Belgium; non-financial support from Novartis, grants from NIH (NIAID/NIAMS) 1UH2AR067691-01 GRANT11652401, and Cedar Hill Foundation; non-financial support for work sponsored by Canadian Institute for Health Research (CIHR), , and personal fees from KAI for NIAMs. Family Member an employee of Brainstorm Therapeutics. In addition Dr Bykerk has participated in research on developing a means for systematic capture of safety data as a member of the OMERACT Safety Steering Committee.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.